CBB1003

an LSD1 histone demethylase inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Carcinogenesis 01/01/2015 - "Using an LSD1 inhibitor, CBB1003, as a probe, we studied the association between LSD1 and leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a CRC stem cell marker involved in carcinogenesis. "
2.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2015 - "CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression."
3.	Neoplasms (Cancer) 01/01/2015 - "The anti-tumor effects of CBB1003 on CRC cells were also examined. " 01/01/2015 - "We also observed the inactivation of β-catenin/TCF signaling after CBB1003 treatment, consistent with the positive correlations among LSD1, LGR5, β-catenin and c-Myc expression in human colon tumor and adenoma tissues. "
4.	Adenoma (Adenomas) 01/01/2015 - "We also observed the inactivation of β-catenin/TCF signaling after CBB1003 treatment, consistent with the positive correlations among LSD1, LGR5, β-catenin and c-Myc expression in human colon tumor and adenoma tissues. "

1.	Catenins
2.	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)
3.	Lysine (L-Lysine)
4.	Leucine (L-Leucine)